AGO TUMOR FUNDAMENTALS EXPLAINED

Hormonal therapy stays the therapy of first choice for metastatic patients with endocrine-responsive breast most cancers (LoE 1a A, AGO ++). The sequential use with the readily available medications will depend on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of analysis of relapse is suggested When feas